INTRODUCTION

Insulin degludec (brand names Ryzodeg, Tresiba, Xultophy) is a an ultra-long-acting insulin analogue that is used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes.

This plasmid is designed for expressing Insulin degludec in yeast expression system Saccharomyces cerevisiae.

PRODUCT INFORMATION

Item No.: PPBD-96
Shipping: Lyophilized plasmid, or liquid plasmid, or plasmids on filter paper
Storage: -20 °C or 4°C according to instruction
Plasmid Backbone: Expression plasmid, flexible options for promoter and selection marker, custom available
Quality Control: Sequencing validation

DRUG INFORMATION

Generic Name: Insulin degludec
Brand Name(s): Ryzodeg, Tresiba, Xultophy
Classification: Hormones, Insulins
Amino Acid Sequence: Identical to DB09564

PROTOCOL FOR PLASMID RECOVERY FROM FILTER PAPER

REFERENCE

[1] Garber AJ, King AB, Del Prato S, Sreenan S, Balci MK, Muñoz-Torres M, Rosenstock J, Endahl LA, Francisco AM, Hollander P; NN1250-3582 (BEGIN BB T2D) Trial Investigators. Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomised, open-label, treat-to-target non-inferiority trial. Lancet. 2012 Apr 21;379(9825):1498-507.

[2] Haahr H, Heise T. A review of the pharmacological properties of insulin degludec and their clinical relevance. Clin Pharmacokinet. 2014 Sep;53(9):787-800.

Contact Us